CG Oncology Stock Forecast

Stock Price Forecast

According to 16 analysts polled by S&P Global, CG Oncology stock has a consensus rating of "Strong Buy" and an average price target of $90.29. The average 1-year stock price forecast is 67.05% higher than the current stock price, while the lowest is $80 (+48.01%) and the highest is $108 (+99.81%).

Price Target: $90.29 (+67.05%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$80	$90.29	$88.5	$108
Change	+48.01%	+67.05%	+63.74%	+99.81%

Analyst Ratings

The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	11	11	11	11	11	11
Buy	4	4	4	4	4	4
Hold	0	0	0	0	0	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	15	15	15	15	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Gregory Renza Truist Financial	Truist Financial	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 27, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Maintains $83 → $87	Buy	Maintains	$83 → $87	+60.96%	May 26, 2026
Kalpit Patel Wolfe Research	Wolfe Research	Hold Maintains n/a	Hold	Maintains	n/a	n/a	May 26, 2026
Robert Driscoll Wedbush	Wedbush	Buy Reiterates $80	Buy	Reiterates	$80	+48.01%	May 18, 2026
Andres Y. Maldonado H.C. Wainwright	H.C. Wainwright	Buy Maintains $100	Buy	Maintains	$100	+85.01%	May 18, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

11.73M

from 4.04M

190.44%

from 4.04M

Revenue Next Year

90.41M

from 11.73M

670.47%

from 11.73M

EPS This Year

-2.66

from -2.08

EPS Next Year

-2.78

from -2.66

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	10.36M	191.00K	204.00K	1.14M	4.04M	11.73M
Revenue Growth	-	-98.16%	6.81%	458.33%	254.70%	190.44%
Gross Profit	-7.96M	-28.84M	-45.55M	-80.96M	-117.25M	2.61M
Gross Margin	-76.86%	-15,098.43%	-22,327.45%	-7,108.25%	-2,902.18%	22.28%
Operating Income	-12.61M	-35.25M	-55.45M	-114.67M	-190.77M	-268.50M
Net Income	-12.84M	-35.44M	-48.61M	-88.04M	-161.00M	-235.67M
EPS	-	-	-	-	-2.08	-2.66
Free Cash Flow	-	-16.95M	-28.07M	-59.08M	-87.62M	-247.01M
No. Analysts	-	-	-	-	-	14

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	104.4M
Avg	11.7M
Low	1.1M

Revenue Growth

Revenue Growth	2026	2027	2028
High	2,483.9%
Avg	190.4%
Low	-73.2%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-2.66
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-